Comparison of two drugs, Lignocaine and Ketamine intravenous infusion in management of difficult cancer pai
Phase 4
- Conditions
- Health Condition 1: C00-D49- Neoplasms
- Registration Number
- CTRI/2023/10/058966
- Lead Sponsor
- Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with Refractory cancer pain with NRS >6-7/10 despite optimal opioid drugs (OME
>300 mg / day)
Patients with refractory neuropathic/mixed pain Patients with life span >8weeks
Exclusion Criteria
H/O psychosis
Any liver, kidney and heart abnormalities Patients with altered cognitive function
H/O drugs hypersensitivity
Patients not giving consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison of Ketamine Vs Lignocaine intravenous infusion in refractory cancer pain in reducing severity of pain atleast by 50%Timepoint: 1 year
- Secondary Outcome Measures
Name Time Method 1.Comparison of side effect profile & tolerability of both drugs <br/ ><br>2.Comparison of time interval in both drugs till next relapse of acute pain crisisTimepoint: 1 year